Roth Capital analyst Tony Butler increased his price target on Replimune (REPL) shares to $30 from $20 after the company reported Q2 updates and presented data over the weekend at the SITC meeting. Replimune developed a new trial protocol in solid organ transplant patients with CSCC and in melanoma patients who are refractory to prior treatment with anti-PD-1 directed therapy, while it also has initiated a registrational phase 2 trial of RP1 in combination with Regeneron's (REGN) anti-PD-1 antibody cemiplimab versus cemiplimab alone, noted Butler, who keeps a Buy rating on Replimune shares.